Tahoe Therapeutics has raised $30 million to develop a large-scale dataset for training Virtual Cell Models. Led by Amplify Partners and supported by investors such as Databricks Ventures and General Catalyst.
This funding will enable the team to create one billion single-cell datapoints and map a million drug-patient interactions, facilitating the development of new precision medicines for cancer and other diseases. Tahoe will choose one partner to access the dataset and speed clinical translation.
Following the release of Tahoe‑100M—the first gigascale perturbative single-cell dataset, which was downloaded nearly 100,000 times—Tahoe aims to further expand by mapping tens of thousands of drugs that interact with human biology. The new dataset is expected to advance foundation models in biology, reduce trial failures, and support the creation of precision therapies.
The company, founded by experts in genomics and drug discovery, is developing scalable single-cell drug screening and plans strategic collaboration with a pharmaceutical or AI partner to combine data and expertise for the first medicines powered by virtual cell models.
KEY QUOTES:
“Building Tahoe-100M required us to invent new ways to generate single-cell data. Now, we’re applying that superpower to go 10x further. This next phase is about using these massive datasets to bring about the GPT moment for AI models of human cells, translating insights to clinical readouts, and developing new medicines with much lower clinical failure rates.”
Nima Alidoust, co-founder and CEO of Tahoe Therapeutics
“While structural models have accelerated molecular design, they rarely translate to clinical success — a problem that remains one of the biggest challenges in drug development. Tahoe Therapeutics is uniquely positioned to move the industry past this bottleneck by generating massive drug-patient datasets and training high-dimensional, cell-based AI models. We’re proud to back this exceptional team as they combine biology and computation to accelerate clinical impact.”
Sunil Dhaliwal, General Partner at Amplify Partners
